Company Overview
Insmed Incorporated operates within the healthcare sector, specifically functioning as a biotechnology company dedicated to developing and commercializing therapies for patients suffering from serious and rare diseases across the United States, Europe, Japan, and internationally. The firm's primary commercial focus includes offering ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, while simultaneously advancing a pipeline through phase 3 clinical trials. As of the latest reporting period, the company holds a substantial market capitalization of $31.04 billion and generates annual revenue of $606.42 million, employing a workforce of 1,664 individuals. These valuation and revenue figures indicate that Insmed is a significant market entity within the biotechnology space, commanding a price-to-sales multiple of 51.18 that reflects high market expectations for its proprietary drug portfolio and future clinical developments.
Financial Health
The company reports a trailing twelve-month revenue of $606.42 million, yet this revenue supports a net income loss of -$1,276,775,040, revealing a cost structure where expenses significantly outweigh top-line earnings. Additionally, the EBITDA stands at -$980,464,000, which further highlights the aggressive investment in research and development or commercialization efforts required to sustain the current business model. Free cash flow for the period is -$534,054,880, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility to fund operations without external capital. Despite these negative income metrics, Insmed maintains a robust cash position of $1.43 billion against total debt of $749.54 million, resulting in a debt-to-equity ratio of 101.43 that suggests a highly leveraged balance sheet relative to its equity base. The gross margin is reported at 79.7%, demonstrating high efficiency in production costs, whereas the operating margin sits at -94.6% and the profit margin at -210.5%, illustrating the severe drag of operating expenses and net losses on profitability. Liquidity is supported by a current ratio of 3.83, which indicates a strong ability to meet short-term obligations with current assets. Return on Equity is -249.3% and return on assets is -29.0%, metrics that reveal management is currently generating negative returns on the capital invested in the company's assets and equity structure.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the net losses, while the forward P/E is listed at 359.96, implying that the market is pricing in significant future earnings recovery or growth to justify the current stock valuation. The price-to-book ratio stands at 41.75, indicating that the market values Insmed at a massive premium over its book value, likely reflecting confidence in the potential of its clinical pipeline and ARIKAYCE sales. Alternative valuation metrics such as the price-to-sales ratio of 51.18 and an EV/EBITDA of -30.96 suggest that traditional multiple-based analysis is less applicable, as the negative earnings drive the EV/EBITDA into negative territory. The stock has demonstrated significant volatility, trading between a 52-week high of $212.75 and a 52-week low of $60.40. Based on the low of $60.40, the current price sits at a level that suggests the stock has recovered from its annual trough but remains below its 52-week peak. The beta value is 1.17, which indicates that the stock is more volatile than the broader market, experiencing price swings that are approximately 17% greater than the market average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is 152.6%, showing a dramatic expansion in sales, whereas earnings growth is N/A due to the company's ongoing losses, implying that top-line expansion is not yet translating into profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all its earnings to reinvest into its research and development activities rather than returning capital to shareholders. Consequently, the overall growth and income profile is characterized by aggressive revenue scaling supported by a strong cash balance but constrained by substantial operating losses that prevent any current income generation for investors.